Study Identifies Population of Cells Serving as the Major Reservoir for HIV

Article

A study published today online in The Journal of Experimental Medicine has identified the population of CD4 T cells serving as the major reservoir for HIV infected cells and as the primary cell site for HIV replication and production in infected patients. The study was led by professor Giuseppe Pantaleo and Dr. Matthieu Perreau at the Division of Immunology and Allergy and at the Swiss Vaccine Research Institute, Lausanne University Hospital in Lausanne, Switzerland.

CD4 T cells are known to be the primary target of HIV. The CD4 T cells serving as reservoir for HIV infection and as primary site for HIV replication and production are not present in the blood and are exclusively found in the lymphoid tissues in a region called germinal centers. These CD4 T cells are called T follicular helper (Tfh) cells: they represent about 2 percent of the total CD4 T cells residing in the lymphoid tissues and are in close contact with B cells and help B cells to mature and produce antibodies.

This is a major discovery for the HIV field; we have finally identified the cell population predominantly responsible for supporting active HIV replication and production, says Pantaleo. We have also provided evidence that the Tfh cells are likely to be responsible for residual virus replication in patients effectively treated with antiretroviral therapy.

HIV-infected Tfh cells hide themselves within the germinal centers where they are difficult to be reached by HIV-specific cytotoxic CD8 T cells, which generally are poorly present in germinal centers, says Perreau. Therefore, germinal centers represent a sanctuary for HIV replication in Tfh cells.

The identification of the major HIV CD4 T cell reservoir will be instrumental in developing therapeutic strategies to selectively target HIV infected Tfh cells, says Pantaleo. The elimination of HIV infected Tfh cells will represent a critical therapeutic strategy to achieve HIV functional cure, i.e., control of HIV replication in the absence of antiretroviral therapy, and potentially HIV eradication.

 

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content